It looks like your browser is not up to date.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Open Orphan subsidiary awarded contract with Oxford BioTherapeutics

Tue 09 March 2021 11:38 | A A A

No recommendation

No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.

(Sharecast News) - Specialist pharmaceuticals contract research organisation Open Orphan announced on Tuesday that its subsidiary Venn Life Sciences had been awarded a contract for a study with clinical-stage oncology company Oxford BioTherapeutics.

The AIM-traded firm said the contract was for a phase 1, open-label dose finding study which would assess the safety, tolerability, pharmacokinetics and preliminary efficacy of 'OBT076', a CD205-directed antibody-drug conjugate, in recurrent and metastatic CD205-positive solid tumours and in women with CD205-positive HER2-negative metastatic breast cancer.

For the study, the Venn team in Paris would provide data management and statistics services.

Open Orphan said Venn's team in Paris was "highly regarded" in the field as a "leading provider" in this area, adding that the study would start immediately.

"We are delighted to be in a position to announce another contract win for the Paris team," said executive chairman Cathal Friel.

"This deal further demonstrates Open Orphan's ability to execute on its significant pipeline of contracts with important pharmaceutical businesses."

Friel described Oxford BioTherapeutics as a clinical stage oncology company with a pipeline of first-in-class therapies, aiming to fulfil "major" unmet patient needs by targeting difficult-to-treat cancers.

"The Venn team are looking forward to assisting with the study and providing the preliminary data required to advance this breast cancer trial."

At 1444 GMT, shares in Open Orphan were down 0.34% at 28.9p.

    The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.


    More company news from ShareCast